



# **Risk Management of Nanomaterials in the Workplace**

**Claude Ostiguy**  
**IRSST**

*ostiguy.claude@irsst.qc.ca*

30<sup>th</sup> International Congress on Occupational Health  
Cancun, Mexico, March 17-23, 2012

# Why nanotechnologies ?


➤ *Unique properties based on the size of the particles and with a different behaviour of the same product at a larger dimension*

- Optical and electrical properties
- Thermal conductivity
- Flexibility, exceptional strength, compressibility
- Large surface area: catalysts, chemical reactivity
- Resistance, lightness
- Melting point

## Optical properties



cm



mm -  $\mu\text{m}$





nm

# Diversity of nanoparticles

## ➤ Creation of numerous new compounds

- Carbon nanotubes, CNT
- Fullerenes
- Quantum dots
- Dendrimers
- Nanoshells ...



## ➤ Nanometric dimensioning of existing products

- Inorganic products ( $\text{TiO}_2$ , metals, metal oxides, ...)
- Organic products (PVC, ...)


# The nanotechnology value chain

## ➤ Investment in research in the United States (2009):

- \$8.5 billion by the government
- \$8.5 billion by companies
- \$750 million in venture capital

## ➤ The 2009 world market:

- nanomaterials (e.g., CNTs): \$1 billion
- nano-intermediates (e.g., catalysts, composites): \$29 billion
- products containing nanos (e.g., electronics): \$224 billion



## ➤ Consumer products

- 1317 products
- 587 companies
- 30 countries

*From the Woodrow Wilson Center site, May 2011*

# A few examples of applications

- **Cosmetics and skin products: ex. TiO<sub>2</sub>**
- **Paints**
- **Computer processors**
- **Antibacterial athletic garments**
- **Skis, tennis rackets, golf clubs**
- **Antibacterial household appliances with a silver coating**
- **Medical diagnostic tools and new therapies**





# Some companies involved in nanotechnology

3M



Kodak




intel.



Honeywell

Lucent Technologies  
Bell Labs Innovations



Agilent Technologies

CORNING

THE DOCUMENT COMPANY  
XEROX

# Hazard anticipation

## At the economic level

- **Unique, unforeseeable properties and major commercial interest**
  - Millions of jobs and hundreds of billions in revenues
  - More than 1300 products already on the market

## At the OHS level

- **Unique, unforeseeable properties and possibly representing new risks...**
  - New behaviours?
  - New risks?

### Unique OHS opportunity

**First subject where prevention can be promoted**

**BEFORE** claims appear

# An evolving workforce

⇒ **Trend: from the research laboratory to industry**

- **Higher potential exposures**
- **Larger number of workers**



- **Nanotechnology is definitely moving towards the manufacturing sector, involving a still limited but growing and often poorly informed workforce**



# Potential emission of nanoparticles

- **In research laboratories**
  - Weighing
  - Drying
  - Manipulation
  - Contamination of tables and equipment
  - Waste...
- **In production plants**
  - Leaks from reactors (high T, colloids ...)
  - Product recovery
  - Post-production treatment
  - Packaging, storing, shipping
  - Equipment maintenance, spills...
- **Use and subsequent transformation**
  - Varied risks depending on uses and specific applications



**Almost all research laboratories, as well as production and transformation processes, are likely to expose workers to NP if good work practices are not implemented**

# Approach to risk management

## *Need for knowledge*

- Toxicology
- Safety
- Epidemiology and surveillance

### **Hazard identification**

**Is there reason to believe that a hazard exists?**

# Do nanoparticles represent a risk to exposed workers?

⇒ Risk =  $f$  {hazard x contamination level}

⇒ Risk(t) =  $f$  {toxicity x exposure}

**In the presence of a hazardous agent, the risk is minimum if there is no contamination**



# Hazard identification: safety aspects

## ➤ Explosion hazard :

- High specific surface area, often involving reactive materials


## ➤ Fire hazard :

- Nanometric metals and high chemical reactivity





# Conditions contributing to explosion/fires





# Potential hazards from inhalation

## ➤ Properties:

- NP developed for their unique chemical/physical properties
  - ➔ could imply increased toxicity

## ➤ Translocation :

- possibility to cross cell boundaries,
- pass directly from the lung into the blood and be distributed to all organs in the body
- Translocate to the brain following deposition in the nose

## ➤ Size:

- Much higher surface area than larger particles
- If surface is a driver for toxicity : increased toxic effects

## ➤ Biopersistent high aspect ratio:

- CNT similar to asbestos?

## ➤ Solubility

- Reduction in size increases solubility: ex. toxic metals

# Documented hazards from inhalation

- **Toxicological studies: still limited but many effects reported**
  - Translocation and distribution in different organs
  - Pulmonary inflammation
  - Oxydative stress
  - Pulmonary granulomas, fibrosis, kidney disorders, cytotoxicity ...
  
- **Toxicity varies from an NP to another**
  - On a mass basis, toxicity is normally more significant with insoluble or partly soluble nanoparticles than with microparticles (same chemical composition)

# Dose - effect relationship: which metrics use?



- Depending on the study, toxicity correlated to :
  - Surface area
  - Number of particles
  - Size distribution
  - Surface activity
  - Various characteristics of an NP
  - **but not to the mass**

# Too soon to come to a conclusion, but...

- **The results of current research suggest that if nanotubes are:**
  - Longer than 20 micrometres,
  - made of aggregates and
  - in sufficient quantity
  
- ❖ **Then we could expect the same types of effects as biopersistent mineral fibres**
  - Fibrosis
  - Cancer
  - Pleural changes
  - Mesothelioma
  
- **Is the situation the same as with asbestos?**

# Approach to risk management

## *Need for knowledge*

- Toxicology
- Safety
- Epidemiology and surveillance
  
- Workplace evaluation
- Material and process characteristics
- Description of processes
- Work methods

### **Hazard identification**

**Is there reason to believe that a hazard exists?**



### **Exposure assessment**

**Is there exposure in an actual situation?**



# Data collection



## ➤ Mass concentration

- Micro-orifice cascade impactors
- Piezoelectric microbalances
- TEOM, ELPI, SMPS...

## ➤ Surface area

- Diffusion charger
- Direct reading instruments
- SMPS, TEM...

## ➤ Number concentrations

- CPC, Electrometers, SMPS, ELPI, SEM, TEM...

## ➤ Granulometric distribution

- SMPS, DEMS, cascade impactors, ELPI, SEM, TEM

## ➤ Chemical composition

- Laboratory techniques (AA, ICP-MS...)

- **ELPI: electrical low pressure impactor**
- **CPC: condensation particle counter**
- **TEM/SEM: transmission and scanning electron microscopes**
- **SMPS: Scanning mobility particle sizer**
- **TEOM: Tapered Element Oscillating Microbalance**
- **DEMS: Differential Electrical Mobility Sizer**

**Personal monitors under development**


# Examples of available equipments



# Approach to risk management


## *Need for knowledge*

- Toxicology
- Safety
- Epidemiology and surveillance
  
- Workplace evaluation
- Material and process characteristics
- Description of processes
- Work methods
  
- Risk assessment: dose and duration
- Dose modeling
- Exposure characterization




# Risk assessment procedure

$$\text{Risk}_{(t)} = f \{ \text{toxicity} \times \text{exposure} \}$$




# Uncertainty management





# Control Banding



# Definition of control levels

		Emission potential bands			
		EB 1	EB2	EB 3	EB 4
Hazard bands	A	CB 1	CB 1	CB 1	CB 2
	B	CB 1	CB 1	CB 2	CB 3
	C	CB 2	CB 3	CB 3	CB 4
	D	CB 3	CB 4	CB 4	CB 5
	E	CB 4	CB 5	CB 5	CB 5

**CL 1: Natural or mechanical general ventilation**


**CL 2: Local ventilation: extractor hood, slot hood, arm hood, table hood, etc.**

**CL 3: Enclosed ventilation: ventilated booth, fume hood, closed reactor with regular opening.**

**CL 4: Full containment: continuously closed systems.**

**CL 5: Full containment and review by a specialist required: seek expert advice.**

# Management as a function of knowledge about the risk




Adapted from Dr. Kuempel, NIOSH

# Approach to risk management

## *Need for knowledge*


- Toxicology
- Safety
- Epidemiology and surveillance
  
- Workplace evaluation
- Material and process characteristics
- Description of processes
- Work methods
  
- Risk assessment: dose and duration
- Dose modeling
- Exposure characterization
  
- Design, Elimination, substitution
- Engineering controls
- Communication about risk and training
- Administrative means
- Personal protective equipment
- Medical surveillance
- Dissemination of information

[www.irsst.qc.ca](http://www.irsst.qc.ca)




# Control of exposure: good IH practices

## Design





# Continuous improvement approach



# Examples of implemented good work practices

## ➤ **Research laboratory :**

- Dr. G. Soucy, Université de Sherbrooke, Qc
- Synthesis of CNT

## ➤ **Industrial production plant:**

- Tekna Advanced Materials, Qc
- Production of nanometric metal, metal oxides and ceramics

# Research Laboratory (CNT)

## ➤ Characteristics:

- Negative pressure
- Central HEPA filtration
- Epoxy painting on the walls
- Two Nano-fume hoods
- One chemical fume hood
- Mobile and fixed ventilation/aspiration systems
- SAS (airlock room)
- Special personal equipment for handling of nano-powders:
  - Tyvek lab coat, powered air purifying respirator (PAPR) with HEPA filtration
- Controlled moisture content @ 40%
- Controlled temperature @ 20 C
- Glove-box cleaning room for synthesis system
- Glove-box for handling of nano-powders
- Emergency showers

# Fully protected worker



- Tyvek suit
- Face shield
- Powered air purifying respirator (PAPR)
- HEPA filtration
- ...

# Homemade glove-box for instrumentation clean-up



- System fully adapted to the research needs



# Laboratory nanohood and mobile local extraction system





# Industrial Production plant

Tekna Advanced Materials, Sherbrooke, Québec



# Design takes risk management into account

**Objective: minimizing the absorbed dose by:**

- **Controlling the exposure level**
- **Minimizing the exposure time/frequency**

**Some possible avenues for minimizing exposure:**

- **Handling nanoparticles in an airtight enclosure (confinement)**
- **Using ventilation at the source if the product must be handled in an open atmosphere**

# Safety Barriers System - Examples

- **Hazard – Production of pyrophoric metals:**
  - **Hydrogen in-situ production rate follows its consumption – no stocking**
  - **Monitoring of residual oxygen concentration in processing vessels**
  - **Controlled passivation of pyrophoric products**
  - **Stocking of pyrophoric products under inert atmosphere**
  - **Equipment designed to withstand deflagration**
  - **Process off gas (already saturated with inerting water vapour) is exhausted to outside through the flash arrestor**

# Safety Barriers System – Nanoparticles Leak

**Barriers level 3** – leak of NP to an external production hall environment

Building kept at negative pressure

HEPA type filtration of air

Wet off gas cleaning

Air lock exit from working area

**Barriers level 2** – exposition of operators to NP

Local Ventilation

Personal Protection Equipment

Wet cleaning

**Barriers level 1** - to prevent a leak of nanoparticles (NP) to the working atmosphere (few examples only)

Processing unit sealed

Pneumatic transport of raw material and products

Deflagration containment design



# Safety Barriers System


- Air lock exit from production hall ⇒
- Personal Protective Equipment



Motorized air blower unit equipped with splash protected gas, vapour & particulates (HEPA class) filtering unit



# Local Ventilation System





# IRSST reports

- **Literature review on health risks related to NP:**
  - R- 451 en français (R-558: deuxième édition, 2008)
  - R- 469 in English (R-589: second Edition, 2008)
- **Literature review of NP health and safety aspects:**
  - R- 455 en français (R-646: Seconde édition : 2009)
  - R- 470 in English (R-656: Second Edition: 2010)
- **Guide of safe practices:**
  - R- 586 en français (2008)
  - R- 599 in English (2009)
  - In Japanese (JNIOOSH web site, 2009)

# State of current knowledge

## • What do we know?

- Potential risks exist
- Exposure situations exist
- NPs can be measured
- NPs can be controlled: Filters and respirators should provide protection
- There is no permissible exposure limits
- There are no specific medical tests but it is prudent to carry out medical surveillance

## • What don't we know?

- The nature and extent of the risk
- The nature and magnitude of the exposure
- What parameter(s) should be measured
- The limitations of the controls and the efficiency of the respiratory protection
- Which standards would be appropriate
- The content of a medical surveillance program

# Our collective challenges



- **Maximize nanotechnology's benefits to society by minimizing or eliminating the environmental impacts and the risks of health and safety impacts for workers and the population**
- **Identify the workplaces that handle nanoparticles**
- **Support them in order to promote the establishment of working conditions for reducing or eliminating occupational exposure**
- **Disseminate the developed knowledge on a broad scale and share expertise**

# Conclusion

- **Nanomaterials can represent specific OHS risks**
- **Toxicity and exposure are only partially documented**
- **Controlling exposure is possible by implementing good IH practices**
- **Keep exposure at a minimum level**
- **Researchers can play a role in prevention by:**
  - **Performing research**
  - **Translating research results to make them comprehensive for a wide audience**
  - **Diffusing and sharing results with the different stakeholders**
  - **Supporting the workplaces in the implementation of good practices**

**Preventionists, universities and companies must be involved in the safe, ethical and responsible development of nanotechnology**

# Questions?



claude.ostiguy@irsst.qc.ca

